Introduction
Protein kinase C (PKC) plays a critical role in integrating and interpreting the signals of the multiple cellular receptors that respond to ligand binding by phospholipase C activation, resulting in the breakdown of phosphoinositides and generation of the lipophilic second messenger sn-1,2-diacylglycerol (DAG). [1] DAG binds to the C1 domains of PKC, both causing enzyme activation and driving its translocation to cellular membranes. This localization, in turn, influences enzyme specificity by controlling the substrates with which it is colocalized. As might be expected from the central role of PKC in cellular-signal processing, PKC has emerged as a promising therapeutic target for cancer chemotherapy. [2] Complementary drug strategies targeting PKC are reflected in inhibitors of PKC catalytic activity such as enzastaurin, [3] inhibitors of PKC expression such as the antisense Aprinocarsen, [4] and potent natural-product mimetics of DAG such as ingenol 3-angelate (PEP005) [5] and bryostatin 1. [6] Bryostatin 1 has attracted considerable attention as a consequence of its paradoxical activity. Whereas it binds to PKC with high affinity, thus leading to enzyme activation, in many biological systems it behaves as a functional antagonist of PMA. It fails to induce the responses observed for PMA and, when coapplied with PMA, it blocks the PMA responses; this confirms that bryostatin 1 is not simply inactive or unstable. [7] Ongoing synthetic efforts with bryostatin derivatives seek to understand the structural features that confer its unique pattern of activity.
[8] Among the biological systems in which the different responses of bryostatin 1 and PMA have been characterized are the LNCaP human prostate cancer cell line [9] and the U937 human leukemia cell line.
[10] In LNCaP cells, whereas PMA induces apoptosis, [11] in part driven by stimulation of TNFa secretion, [9c, 12] bryostatin 1 does not. [9] In U937 cells, PMA inhibits proliferation and induces cell attachment, whereas bryostatin 1 has a much reduced effect. [10] In both systems, bryostatin 1 anPhorbol 12-myristate 13-acetate (PMA) and bryostatin 1 are both potent protein kinase C (PKC) activators. In LNCaP human prostate cancer cells, PMA induces tumor necrosis factor alpha (TNFa) secretion and inhibits proliferation; bryostatin 1 does not, and indeed blocks the response to PMA. This difference has been attributed to bryostatin 1 not localizing PKCd to the plasma membrane. Since phorbol ester lipophilicity influences PKCd localization, we have examined in LNCaP cells a series of phorbol esters and related derivatives spanning some eight logs in lipophilicity (logP) to see if any behave like bryostatin 1.
The compounds showed marked differences in their effects on proliferation and TNFa secretion. For example, maximal responses for TNFa secretion relative to PMA ranged from 97 % for octyl-indolactam V to 24 % for phorbol 12,13-dibenzoate.
Dose-response curves ranged from monophasic for indolactam V to markedly biphasic for sapintoxin D. The divergent patterns of response, however, correlated neither to lipophilicity, to plasma membrane translocation of PKCd, nor to the ability to interact with model membranes. In U937 human leukemia cells, a second system in which PMA and bryostatin 1 have divergent effects, viz. PMA but not bryostatin 1 inhibits proliferation and induces attachment, all the compounds acted like PMA for proliferation, but several induced a reduced level or a biphasic dose-response curve for attachment. We conclude that active phorbol esters are not all equivalent. Depending on the system, some might partially resemble bryostatin 1 in their behavior; this encourages the concept that bryostatin-like behavior may be obtained from other structural templates.
tagonizes the effect of PMA, thereby confirming that bryostatin 1 is not simply inactive in these systems. Mechanistic analysis by von Burstin and Kazanietz [9c] suggested that the basis for the difference in behavior of PMA and bryostatin 1 in LNCaP cells was that PMA induced plasma membrane translocation of PKCd, whereas bryostatin 1 did not. In support of this conclusion, when a modified PKCd that had a myristoylation site incorporated at its C terminus to drive plasma membrane association was expressed in LNCaP cells, bryostatin 1 then behaved like PMA, inducing TNFa secretion and inhibiting growth.
We have previously described how, in Chinese hamster ovary (CHO) cells, PMA caused PKCd to translocate initially to the plasma membrane, followed by partial redistribution to the nuclear membrane and other internal membranes. Bryostatin 1, in contrast, failed to cause initial translocation to the plasma membrane but rather caused direct translocation to internal membranes. [13] Examination of a series of phorbol esters and related derivatives showed that the lipophilicity of the compounds determined the pattern of translocation of PKCd, with more-lipophilic compounds behaving like PMA and lesslipophilic compounds behaving like bryostatin 1. [14] If, as suggested by von Burstin and Kazanietz,
[9c] the failure of bryostatin 1 to induce TNFa secretion and inhibit proliferation in the LNCaP cells resulted from the lack of plasma membrane translocation of PKCd, one prediction is that less-lipophilic phorbol esters should be bryostatin 1 mimetics.
In this study, we evaluated a series of diverse phorbol esters and related PKC ligands in two well-characterized systems in which bryostatin 1 has been shown to fail to induce prominent responses induced by PMA and to block those responses when administered together with PMA. These systems were chosen because it is these differences that make bryostatin 1 of particular therapeutic interest. We address two related questions. Is the behavior of bryostatin 1 in these systems truly unique to bryostatin 1 or is it mimicked by some phorbol esters? Can the lipophilicity of the ligands (and their resultant differential localization of PKCd) account for the patterns of biological response that they induce?
Results
We selected a series of commercially available phorbol esters, ingenols, indolactams, and sapintoxin D (Scheme 1) that span close to nine orders of magnitude in lipophilicity, with calculated logP values ranging from 0.07 to 8.8 (Table S1 in the Supporting Information and Figure 1) . These values bracket the experimentally determined logP value of bryostatin 1, which was 2.88. [15] As a further criterion, we tried to select compounds with divergent structural features or unusual patterns of biological activity. Prostratin is anti-tumor promoting [16] and has been suggested to be of therapeutic utility for abolishing HIV latency.
[17] Ingenol 3-angelate, which is in clinical trials for skin cancer, [5, 18] differs from typical phorbol esters in the pattern of biological response both in WEHI-231 cells [19] and in mouse skin, [20] and, as an ingenol 3-ester, has its hydrophobic domain differently oriented relative to the diterpene moiety compared to the phorbol esters. [21] Sapintoxin D has been used to define differential binding affinities for the C1 domains of PKC and has weak tumor-promoting activity.
[22] Phorbol 12,13-dibenzoate is very weak as a tumor promoter. [23] Indolactams are the simplest members of the teleocidin family with high inflammatory and tumor-promoter activity.
[24] All of the compounds are ligands for PKC, binding to the C1 domain competitively with phorbol 12,13-dibutyrate. Binding affinities for PKC varied somewhat, with reported K i values ranging from 0.1 to 10 nm (65 nm for phorbol 12,13-diacetate).
In LNCaP cells, PMA causes marked inhibition of cell growth after 72 hours. In contrast, although bryostatin 1 is not without effect, the maximal level of inhibition was only 19.6 % of that for PMA ( Figure 1 , Table 1 ). These results are similar to those observed by us and others previously. Among the series of other phorbol esters and related derivatives, the first striking finding was that their maximal response varied dramatically (Table 1) . Several of the compounds, in particular the two indolactams, were even more effective than PMA at inhibiting growth. In contrast, phorbol 12,13-dibenzoate was only slightly more effective than bryostatin 1; maximal inhibition of growth was only 14 % greater. Several other derivatives, sapintoxin D, prostratin, and phorbol 12,13-dihexanoate, yielded an intermediate but still weak response, followed by phorbol 12,13-dibutyrate and phorbol 12,13-didecanoate. A second feature of the dose response curves was the extent to which they were biphasic. Phorbol 13-decanoate at a maximally effective dose (1000 nm) reached 92 % of the PMA response, whereas a tenfold higher dose gave no more inhibition than did bryostatin 1. In contrast, little biphasic response was seen for some of the other derivatives, such as indolactam V or phorbol 12,13-diacetate. We conclude that the failure to inhibit cell growth in the LNCaP cells among PKC activators is not limited to bryostatin 1. Rather, PKC ligands show a continuum of extents of inhibition of LNCaP cell growth.
The induction of TNFa secretion is a major, although not the only, contributor to the inhibition of LNCaP cell growth in response to PMA. Roughly in parallel with their abilities to inhibit cell growth, the phorbol esters and related derivatives that we examined varied in their abilities to induce TNFa secretion ( Figure 2 , Table 1 ). Thus, octyl-indolactam V induced TNFa to a level comparable to that induced by PMA, whereas phorbol 12,13-dibenzoate at its maximally effective dose induced only 24 % of that level. Sapintoxin D was somewhat more effective than expected from its weak inhibition of growth, but the dose-response curve was markedly biphasic, with a dose of 10 000 nm giving only 5 % of the maximal level of secretion induced by PMA. Once again, our data strongly argue that the phorbol esters Figure 1 . PKC ligands vary greatly in how much they inhibit LNCaP cell growth and the degree to which these dose-response curves are biphasic. LNCaP cells were treated for 72 h with the indicated compounds (doses increase from left to right in half-log increments for all effective doses; see Table S1 ). Compounds are aligned based on their lipophilicity (logP values; top). Growth inhibition was normalized as described in the Experimental Section. Values represent the mean AE SEM of at least four independent experiments (n = 4 to 9). Biological response Growth of LNCaP cells [b] TNFa secretion from LNCaP cells [b] Growth of U937 cells [b] Attachment of U937 cells [b] phorbol esters max inhibition [c] IC 50 [nm] [c] max secretion [d] EC 50 and EC 50 were calculated based on 50 % of the maximal response for the specific ligand. The values would be modestly different if another basis were used for the calculations but, since we do not know the mechanism accounting for the biphasic curves, we do not know if another basis would be preferable.
[f] Not determined because of low signal intensity or very few point for the first phase of the biphasic curve.
and related derivatives are not all equivalent but vary markedly in the extents of TNFa secretion that they are able to induce. As with the findings for growth, however, all of the derivatives were at least modestly more effective for inducing TNFa secretion than was bryostatin 1. When comparing the maximal extents of TNFa secretion induced by the various phorbol esters and related derivatives in the LNCaP cells with the calculated logP values of the compounds, we found that all of the compounds that induced a lower maximal response than did PMA possessed logP values between 2 and 5 (Table S1 ). On the other hand, some of the compounds in this logP range induced levels of TNFa secretion similar to PMA; this indicates that a logP value within this range was not sufficient to endow the phorbol ester with reduced activity for inducing TNFa secretion.
We have previously characterized the pattern of PKCd subcellular localization in CHO cells in response to PMA, bryostatin 1, and a series of phorbol esters that varied in their lipophilicities. [13, 14] For direct comparison, we determined how the ligands of the current study affect PKCd localization in LNCaP cells. Visualizing PKCd localization using a GFP-PKCd construct, we found that PKCd responded more or less similarly in the LNCaP cells to what we had described earlier in the CHO cells (Figure 3) . PKCd initially translocated to the plasma membrane in response to PMA, subsequently partially redistributing to the nuclear membrane and internal membranes. A similar pattern was observed for phorbol 12,13-decanoate, albeit with a slower rate of translocation. Bryostatin 1 caused modestly more plasma membrane translocation than we had observed in the CHO cells. The less-lipophilic ligands predominantly caused translocation to internal membranes, with little plasma membrane localization. Little difference was observed between compounds that caused more or less inhibition of growth/TNFa secretion.
Next, we examined U937 human leukemia cells. In this system, PMA inhibits cell growth, whereas bryostatin 1 again has a much reduced effect. All the phorbol esters and related derivatives that we examined showed behavior basically similar to that of PMA ( Figure 4 , Table 1 ). PMA induced 54 % inhibition of growth in this series of experiments. Inhibition by the other phorbol esters and related derivatives ranged from 46 to 65 %. In contrast, maximal inhibition in response to bryostatin 1 treatment was only 20 %. While none of the phorbol esters or related derivatives resembled bryostatin 1 in this system for inhibition of proliferation, it should be noted that the limited differences observed reflected the pattern of selectivity seen with the LNCaP cells. Thus, phorbol 12,13-dibenzoate and sapintoxin D induced a little less inhibition than the other compounds or PMA; indolactam V induced a little more inhibition. These differences, while small, were statistically significant (p < 0.03).
Attachment to the substratum is a second response of the U937 cells that differentiates between PMA and bryostatin 1. PMA induces attachment whereas bryostatin 1 has little effect. For the series of phorbol esters and related derivatives examined, the overall pattern resembles that seen for inhibition of proliferation in this cell type (Figure 5 A, Table 1 ). All of the compounds induced attachment, with maximal levels of the total number of cells becoming attached ranging from 53 to 76 %. In contrast, bryostatin 1 induced only 9 %. More diversity is observed in the dose-response relationships. Dose-response curves for some of the compounds were markedly biphasic, whereas in other cases, little suppression was seen for doses above those inducing a maximal response. Again, sapintoxin D, phorbol 12,13-dibenzoate, and phorbol 12,13-dihexanoate showed the most suppression at high doses. Indolactam V, octyl-indolactam V, and ingenol 3-angelate showed the least suppression. In parallel with the effect of bryostatin 1, combination of a suppressing concentration of the phorbol derivative together with PMA largely resembled the effect of the suppressing concentration of the phorbol derivative alone (Figure 5 B) . Just as bryostatin 1 showed much less induction of attachment, it was correspondingly much more effective at blocking attachment in combination.
To determine whether we could detect any unique pattern of membrane interaction among those derivatives that showed a lesser extent of PMA-like activity in any of the biological assays, we assessed their ability to insert into artificial membranes ( Figure S1 ). We have previously described the use of mixed membranes of dimyristoylphosphatidylcholine into which polydiacetylene (PDA) patches are incorporated. Interaction of lipophilic molecules with the membranes induces fluorescent signals from the PDA patches, [25] and this technique has proven useful for evaluating the interaction of DAG-lactones with membranes. [26] In the lipid/PDA vesicle system, the Figure 2 . PKC ligands vary greatly in how much TNFa they induce LNCaP cells to secrete and the degree to which these dose-response curves are biphasic. LNCaP cells were treated for 24 h with the indicated compounds (aligned based on lipophilicity; doses increase from left to right in half-log increments for all effective doses; for treatment details see Table S1 ), and the TNFa secreted into the supernatant was measured by ELISA. Data were normalized to the maximal response induced by 10 nm PMA. Values represent the mean AE SEM of at least three independent experiments (n = 3 to 9).
www.chembiochem.org www.chembiochem.org extent of membrane interaction corresponded to the lipophilicity of the molecules, thus suggesting that the uniqueness of the compounds that were less PMA-like could not be attributed to distinct membrane interactions, at least as far as can be detected by this method.
Discussion
Bryostatin 1 stands apart from PMA in the very different pattern of biological responses that it induces. In contrast, it has long been considered that the various phorbol esters have generally similar biological effects, albeit they may differ substantially in potency. [27] Nonetheless, at the whole-animal level, there are limited examples of different phorbol esters and related derivatives causing different responses. Most dramatically, the relatively hydrophilic (less-lipophilic) derivatives 12-deoxyphorbol 13-acetate (prostratin) and 12-deoxyphorbol 13-phenylacetate inhibit tumor promotion, whereas PMA is tumor promoting; [16] in addition, these compounds inhibit some of the other Table 1 ). The number of cells (attached and unattached) were counted and are shown as a percentage of the DMSO-treated control cells. The mean and SEM of at least three independent experiments (n = 3 to 9) are shown.
PMA-induced responses in mouse skin.
[28] Likewise, in mouse skin, phorbol derivatives with unsaturated side chains tend to be inflammatory but not tumor promoting, whereas their saturated derivatives are both inflammatory and tumor promoting. [29] Such differences, of course, could reflect issues of drug absorption and stability in the whole animal.
Recent advances have suggested, however, that the differences in the patterns of biological response to phorbol esters and other PKC activators could be more profound. For example, analysis of combinatorial libraries of DAG lactones, potent synthetic PKC ligands, indicated marked diversity in selectivity for different cellular assays. [30] Likewise, it is abundantly clear that different phorbol esters and related derivatives might have different selectivity in cells for different isoforms. [19, 31] Since different PKC isoforms have different effects, differences in structure-activity relations would be predicted to lead to different patterns of cellular response. [2] Moreover, it is now recognized that the PKC family of isoforms is only one of seven families of proteins with C1 domains that recognize diacylglycerol, phorbol esters, and related derivatives.
[2] Further, we have described ligands with selectivity for RasGRP3 compared to PKC isoforms. [31, 32] Such diversity suggests that PKC ligands might afford a richer fund of therapeutic biomolecules than was initially recognized. [7] Indeed, ingenol 3-angelate (PEP005), which is isolated from herbal preparations of Euphorbia peplus, is currently in phase III clinical trials (http://www.clinicaltrials.-gov) for actinic keratosis and basal cell carcinoma.
Our findings provide unambiguous answers to the two issues motivating this study. First, can the difference in pattern of membrane localization of PKCd induced by PMA and bryostatin 1 account for the different patterns of response in the LNCaP cells? Clearly it cannot at the level of resolution provided by the GFP-PKCd constructs and by differences in lipophilicity. This is important, because it argues that the lack of plasma membrane localization is not the robust measure of bryostatin-like activity for which it has sometimes been taken. [33] On the other hand, our findings should not be overinterpreted. Our results do not address whether localization at a higher level of resolution might be relevant or whether localization in combination with other factors might be determinative.
The second issue is whether the special pattern of biological activity of bryostatin 1 is unique to the bryostatin structural template or whether it could be more generalizable. Our findings indicate that, in the LNCaP system, the difference between bryostatin 1 and phorbol esters is not so great; in contrast, the difference is appreciably larger in the U937 leukemia cells. We conclude that the U937 cell system provides a more stringent test of the homologous behavior of other ligands with bryostatin 1. A further conclusion is that the difference between bryostatin 1 and the phorbol derivatives examined here seems more quantitative than qualitative. The assays can be ranked in the following order of decreasing stringency: inhibition of proliferation of the U937 cells, induction of attachment of the U937 cells, inhibition of proliferation of the LNCaP cells, and induction of TNFa secretion in the LNCaP cells. The inhibition of proliferation of the U937 cells is the most demanding for homology; the induction of TNFa secretion is the least demanding. This continuum in behavior implies that the underlying mechanisms, at least for these responses that differentiate PMA and Figure 5 . PKC ligands except for bryostatin 1 induce differentiation of U937 cells as indicated by attachment to the substratum and some show a biphasic response. Those PKC ligands that suppress cell attachment at high doses also antagonize the effect of PMA at these doses, as does bryostatin 1. U937 cells were treated with A) the indicated compounds for 72 h (increasing concentrations from left to right in log increments; see details in Table S1 ) or B) 10 nm PMA and 1000 nm of the indicated compounds (10 000 nm for prostratin, phorbol diacetate, indolactam V). The numbers of attached and total cells were counted; the attached cells are shown as a percent of the total cells. The mean and SEM of at least three independent experiments (n = 3 to 7) are shown. bryostatin 1 in these cell types, will be differences in degree of action.
It is important that the great sophistication demanded in the design and synthesis of novel bryostatin 1 analogues targeted for cancer chemotherapy is complemented by appropriate insights into the biological systems for testing these analogues. Our studies provide guidance in this effort.
Experimental Section
Materials: All phorbol ester derivatives were purchased from LC Laboratories (Woburn, MA). Sapintoxin D was from Enzo Life Sciences International Inc. (Plymouth Meeting, PA). The bryostatin 1 was provided by the Developmental Therapeutics Program, NCI (Frederick, MD). The LNCaP human prostate cancer cell line, the U937 human monocytic cell line, fetal bovine serum (FBS), and RPM1-1640 medium were obtained from ATCC (Manassas, VA). Growth of LNCaP cells: The growth of LNCaP cells was expressed as the difference in cell confluency before and 72 h after treatment. The confluency of LNCaP cells was followed in real time on an IncuCyte Imaging instrument (Essen Instruments, Ann Arbor, MI). LNCaP cells were plated onto 48-well plates (25 000 cells per well), then treated 48 h later with the indicated compounds at different concentrations (final DMSO concentration 0.1 % for each treatment). Phase-contrast images of the cells were taken every 2-4 h by the instrument for four days. The difference in confluency between 0 and 72 h was calculated for each compound by the instrument's program, subtracted from the difference for the DMSO control, and normalized to the maximal PMA response (10 nm). Measurement of TNFa: 180 000 cells per well were plated on 24 well plates, then treated 24 h later with the indicated drugs. The supernatants were collected 24 h after treatment, then centrifuged (4000 rpm for 5 min in an Eppendorf microcentrifuge) to remove any cells, and TNFa levels were measured by ELISA according to the manufacturer's (Invitrogen) instructions. Translocation of GFP-tagged PKC isoforms in LNCaP cells: Translocation of PKCd was evaluated as described before [13] with some modifications. 60 000 LNCaP cells were plated on Ibi-treated dishes (Ibidi LLC, Verona, WI), then transfected 48 h later with GFP-tagged PKCd by using Lipofectamine reagent in combination with Plus reagent according to the manufacturer's (Invitrogen) recommendations. After 24 h, the cells were treated with the indicated drugs in confocal medium (Dulbecco's Modified Eagle Medium without phenol red supplemented with 1 % FBS), and time-lapse images were collected every 30 s by using the Zeiss AIM software. The cells were examined in a Zeiss LSM 510 confocal microscopy system (Carl Zeiss, Inc.) with an Axiovert 100 m inverted microscope operating with a 25 mW argon laser tuned to 488 nm. Cells were imaged with a 63 1.4 NA Zeiss Plan-Apochromat oil-immersion objective and with varying zooms (1.4 to 2 ). The growth and attachment of U937 cells were measured as described earlier.
[8a] U937 cells were plated in 35 mm dishes at a density of 1 10 5 living cells per mL, then treated 24 h later with different concentrations of the drugs or DMSO (diluent concentration in each sample was 0.1 %). After 72 h, the number of unattached cells present in the supernatant and the number of attached cells (determined after trypsinization) were counted by using a Beckman particle counter (Beckman Coulter Inc., Fullerton, CA). The number of attached cells was expressed as percent of total cells. Dose-response curves and statistical analysis: The concentrations of the compounds used in the different biological assays and their logP values are listed in Table S1 . Values listed in the text, unless otherwise noted, represent the mean AE SEM from at least three independent experiments. The statistical significance was determined by using a Student's two-tailed t-test.
